{
    "clinical_study": {
        "@rank": "142758", 
        "arm_group": [
            {
                "arm_group_label": "50 mg of AVL-292 and Placebo", 
                "arm_group_type": "Experimental", 
                "description": "50 mg AVL-292"
            }, 
            {
                "arm_group_label": "100 mg of AVL-292 and Placebo", 
                "arm_group_type": "Experimental", 
                "description": "100 mg AVL-292"
            }, 
            {
                "arm_group_label": "200 mg of AVL-292 and Placebo", 
                "arm_group_type": "Experimental", 
                "description": "200 mg AVL-292"
            }, 
            {
                "arm_group_label": "350 mg of AVL-292 and Placebo", 
                "arm_group_type": "Experimental", 
                "description": "350 mg AVL-292"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 2-part study.  The first part is to evaluate the safety, pharmacokinetics and\n      pharmacodynamics of AVL-292 following multiple oral doses; and the second part is to\n      evaluate the effect of food on the pharmacokinetics of a single oral dose of AVL-292."
        }, 
        "brief_title": "Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male or female subjects of any ethnic origin between ages of 18 and 65 with a\n             body mass index between 18 and 33\n\n        Exclusion Criteria:\n\n          -  Recent history (i.e., within 3 years) of any clinically significant neurological,\n             gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, endocrine,\n             hematological, dermatological, psychological, ophthalmological, allergic or other\n             major disorders;\n\n          -  Use of any prescribed systemic or topical medication within 30 days of the first\n             dose;\n\n          -  Use of any non-prescribed systemic or topical medication (including vitamin/mineral\n             supplements and herbal medicines, e.g., St. John's Wort) within 7 days of the first\n             dose administration;\n\n          -  Exposure to an investigational drug (new chemical entity) within 30 days prior to the\n             first dose administration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692184", 
            "org_study_id": "AVL-292-004"
        }, 
        "intervention": [
            {
                "arm_group_label": "50 mg of AVL-292 and Placebo", 
                "description": "50 mg AVL-292 (2X 25 mg AVL-292 capsules and 6 placebo capsules) once daily for 7 days administered orally under fasted condition", 
                "intervention_name": "50 mg of AVL-292", 
                "intervention_type": "Drug", 
                "other_name": "AVL-292"
            }, 
            {
                "arm_group_label": "100 mg of AVL-292 and Placebo", 
                "description": "100 mg AVL-292 (4X 25 mg AVL-292 capsules and 4 placebo capsules) once daily for 7 days administered orally under fasted condition", 
                "intervention_name": "100 mg of AVL-292", 
                "intervention_type": "Drug", 
                "other_name": "AVL-292"
            }, 
            {
                "arm_group_label": "200 mg of AVL-292 and Placebo", 
                "description": "200 mg AVL-292 (8X 25 mg AVL-292 capsules and 8 placebo capsules) once daily for 7 days administered orally under fasted condition.", 
                "intervention_name": "200 mg of AVL-292", 
                "intervention_type": "Drug", 
                "other_name": "AVL-292"
            }, 
            {
                "arm_group_label": "350 mg of AVL-292 and Placebo", 
                "description": "350 mg AVL-292 (14X 25 mg AVL-292 capsules and 14 placebo capsules) once daily for 7 days administered orally under fasted condition", 
                "intervention_name": "350 mg of AVL-292", 
                "intervention_type": "Drug", 
                "other_name": "AVL-292"
            }, 
            {
                "arm_group_label": [
                    "50 mg of AVL-292 and Placebo", 
                    "100 mg of AVL-292 and Placebo", 
                    "200 mg of AVL-292 and Placebo", 
                    "350 mg of AVL-292 and Placebo", 
                    "Placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "AVL-292", 
            "Safety", 
            "Pharmacokinetics", 
            "Pharmacodynamics", 
            "Pharmacology, Clinical"
        ], 
        "lastchanged_date": "October 5, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }, 
                "name": "Covance Clinical Research Unit"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 1, Two-part Study to Investigate the Safety and Pharmacokinetics of AVL-292 Following Multiple Oral Doses and to Evaluate the Effect of Food on the Pharmacokinetics of Avl-292 Following a Single Oral Dose in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Maria Palmisano, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Number of participants with adverse events", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days after last AVL-292 dose"
            }, 
            {
                "description": "Maximum observed concentration in plasma", 
                "measure": "PK-(Cmax)", 
                "safety_issue": "No", 
                "time_frame": "24 hours after the last AVL-292 dose on days 1 and 7"
            }, 
            {
                "description": "Area under the plasma concentration-time curve", 
                "measure": "PK-(AUC)", 
                "safety_issue": "No", 
                "time_frame": "24 hours after the last AVL-292 dose days 1 and 7"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692184"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Pharmacodynamic response measured in percentage of target occupancy by AVL-292 in peripheral blood mononuclear cells", 
            "measure": "Pharmacodynamic response measured in percentage of target occupancy by AVL-292 in peripheral blood mononuclear cells", 
            "safety_issue": "No", 
            "time_frame": "24 hours after the last AVL-292 dose days 1 and 7"
        }, 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}